A chimeric cytokine receptor, which comprises a truncated il2rbeta and il2rgamma

HK40137325APending Publication Date: 2026-09-11AUTOLUS LIMIED
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026123720
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-20
Filing Date
2026-05-20
Publication Date
2026-09-11

Smart Images

  • Figure 00000076_0000
    Figure 00000076_0000
  • Figure 00000077_0000
    Figure 00000077_0000
  • Figure 00000077_0001
    Figure 00000077_0001
Patent Text Reader

Abstract

The present invention provides a chimeric cytokine receptor comprising a cytokine receptor endodomain which comprises a first chain and a second chain, wherein both the first and second chain of the cytokine-receptor endodomain are truncated. The invention also provides cells comprising such a chimeric cytokine receptor, optionally in combination with a chimeric antigen receptor (CAR) and their use in the treatment of diseases such as autoimmune diseases and cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Abstract This invention provides a chimeric cytokine receptor comprising an intracellular domain of a cytokine receptor, the intracellular domain comprising a first strand and a second strand, wherein both the first and second strands of the intracellular domain of the cytokine receptor are truncated. The invention also provides cells comprising such a chimeric cytokine receptor, optionally in combination with a chimeric antigen receptor (CAR), and its use in the treatment of diseases such as autoimmune diseases and cancer.

Claims

CLAIMS1. A chimeric cytokine receptor, which comprises two polypeptides:(i) a first polypeptide which comprises:(a) a first dimerization domain; and(b) a truncated IL2 receptor p-chain endodomain which comprises the sequence shown as SEQ ID No. 2 with a C-terminal truncation of between about 10 and about 70 amino acids; and(ii) a second polypeptide which comprises:(a) a second dimerization domain which dimerises with the first dimerization domain; and(b) a truncated common y-chain endodomain which comprises the sequence shown as SEQ ID No. 1 with a C-terminal truncation of between about 10 and about 30 amino acids.

2. A chimeric cytokine receptor according to claim 1, wherein the truncated IL2 receptor p-chain endodomain of the first polypeptide has the sequence shown as SEQ ID No. 58.

3. A chimeric cytokine receptor according to claim 1 or 2, wherein the truncated common y-chain endodomain of the second polypeptide has the sequence shown as SEQ ID No. 62.

4. A chimeric cytokine receptor according to any preceding claim, wherein the first and second dimerization domains dimerise spontaneously.

5. A chimeric cytokine receptor according to any preceding claim, where the first and second dimerization domains dimerise in the presence of a chemical inducer of dimerization (CID) or the presence of a ligand.

6. A chimeric cytokine receptor according to claim 4 wherein: the first dimerization domain comprises a heavy chain constant domain (CH) and the second dimerization domain comprises a light chain constant domain (CL); or the first dimerization domain comprises a light chain constant domain (CL) and the second dimerization domain comprises a heavy chain constant domain (CH).

7. A chimeric cytokine receptor according to claim 5 which comprises two polypeptides:(i) a first polypeptide which comprises:(a) a first antigen-binding domain which binds a first epitope of the ligand; and(b) a truncated IL2 receptor p-chain endodomain which comprises the sequence shown as SEQ ID No. 2 with a C-terminal truncation of between about 10 and about 70 amino acids; and(ii) a second polypeptide which comprises:(a) a second antigen-binding domain which binds a second epitope of the ligand; and(b) a truncated common y-chain endodomain which comprises the sequence shown as SEQ ID No. 1 with a C-terminal truncation of between about 10 and about 30 amino acids.

8. A chimeric cytokine receptor according to claim 7, wherein each of the first and second antigen-binding domains are single-chain variable fragments (scFvs).

9. A chimeric cytokine receptor according to claim 7, wherein each of the first and second antigen-binding domains are single domain binders (dAbs).

10. A chimeric cytokine receptor according to claim 5, which comprises two polypeptides:(i) a first polypeptide which comprises:(a) a heavy chain variable domain (VH)(b) a truncated IL2 receptor p-chain endodomain which comprises the sequence shown as SEQ ID No. 2 with a C-terminal truncation of between about 10 and about 70 amino acids; and(ii) a second polypeptide which comprises:(a) a light chain variable domain (VL)(b) a truncated common y-chain endodomain which comprises the sequence shown as SEQ ID No. 1 with a C-terminal truncation of between about 10 and about 30 amino acids wherein the VH and VL associate forming a ligand-binding site.

11. A chimeric cytokine receptor according to any of claims 7 to 10, wherein the ligand is a tumour secreted factor selected from: prostate-specific antigen (PSA),carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF) and CA125.

12. A chimeric cytokine receptor according to any of claims 7 to 10, wherein the ligand is a chemokine selected from: CXCL12, CCL2, CCL4, CCL5 and CCL22.

13. A cell which comprises a chimeric cytokine receptor according to any preceding claim.

14. A cell according to claim 13, which also comprises a chimeric antigen receptor.

15. A nucleic acid construct encoding a chimeric cytokine receptor according to any of claims 1 to 13 which comprises a first nucleic acid sequence encoding the first polypeptide; and a second nucleic acid sequence encoding the second polypeptide.

16. A nucleic acid construct according to claim 15 which also encodes a chimeric antigen receptor (CAR).

17. A nucleic acid construct according to claim 15 or 16 which comprises an MND promoter.

18. A vector comprising a nucleic acid construct according to any of claims 15 to 17.

19. A vector according to claim 18 which is a lentiviral vector.

20. A kit which comprises: i) a vector comprising a nucleic acid sequence encoding a first polypeptide as defined in any of claims 1 to 13; and ii) a vector comprising a nucleic acid sequence encoding a second polypeptide as defined in any of claims 1 to 13.

21. A kit according to claim 20 which also comprises a vector comprising a nucleic acid sequence encoding a chimeric antigen receptor.

22. A method for making a cell according to claim 13 or 14, which comprises the step of introducing: a nucleic acid construct according to any of claims 15 to 17; a vector according to claim 18 or 19; or a kit of vectors according to claim 20 or 21, into a cell ex vivo.

23. A method according to claim 22, wherein the cell is from a sample isolated from a subject.

24. A pharmaceutical composition comprising a plurality of cells according to claim 13 or 14.

25. A method for treating a disease, which comprises the step of administering a pharmaceutical composition according to claim 24 to a subject.

26. A method according to claim 25, which comprises the following steps:(i) isolation of a cell-containing sample from a subject;(ii) transduction or transfection of the cells with: a nucleic acid construct according to any of claims 15 to 17; a vector according to claim 18 or 19; or a kit of vectors according to claim 20 or 21; and(iii) administering the cells from (ii) to the subject.

27. A method according to claim 26, wherein the sample is a T-cell containing sample.

28. A method according to claim 26 or 27, wherein the disease is a cancer, an infectious disease or an autoimmune disease.

29. A pharmaceutical composition according to claim 24 for use in treating a disease.

30. The use of a cell according to claim 13 or 14 in the manufacture of a medicament for treating a disease.